Lyterian Therapeutics is committed to developing transformative medicines for patients by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically-validated targets.
Lyterian is derived from λυτήριος or lutḗrios, which means termination, healing, or end of disease.
Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. We are inspired to learn from the logic that orchestrates homeostatic equilibria and drives healing, and incorporate these learnings in the design of our medicines.
Stanford University
UC Berkeley, HHMI
UC Berkeley, HHMI
Stanford University
Genentech, BMS
We have big dreams yet know the importance of celebrating the small wins. We bring passion and enthusiasm to our work, inspiring the contributions of others, while making sure to have fun along the way.
We embrace challenges, take responsibility, and strive to improve each and every day. We hold a growth mindset and take risks without fear of failure. We courageously empower ideas and action in pursuit of patient impact.
We show up for one another, share generously, build trust and act with compassion. We embrace being a force for good and strive to do what is right.
We are greater than the sum of our parts. We believe that collaboration fuels our success and that synergies arise through transparent flow, diverse perspectives and courageous feedback.
We balance our enthusiasm with diligent focus on patients in need. This requires us to move with urgency, follow the data, challenge our thinking and be intentional about our priorities.
630 Gateway Blvd, South San Francisco, CA 94080 - Copyright © 2023 Lyterian Therapeutics - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.